Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
IPO Year: 2013
Exchange: NASDAQ
Website: arcturusrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/18/2026 | $22.00 | Buy | B. Riley Securities |
| 1/23/2026 | $20.00 | Buy | Roth Capital |
| 10/24/2025 | $12.00 | Buy → Neutral | H.C. Wainwright |
| 10/23/2025 | $12.00 | Buy → Neutral | Citigroup |
| 10/22/2025 | Buy → Neutral | Guggenheim | |
| 9/4/2025 | $60.00 | Buy | H.C. Wainwright |
| 5/28/2025 | $32.00 | Sector Outperform | Scotiabank |
| 1/28/2025 | $41.00 | Buy | BTIG Research |
| 8/12/2024 | $70.00 | Outperform | Leerink Partners |
| 12/13/2023 | $90.00 | Buy | Canaccord Genuity |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
B. Riley Securities initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $22.00
Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00
H.C. Wainwright downgraded Arcturus Therapeutics from Buy to Neutral and set a new price target of $12.00
Citigroup downgraded Arcturus Therapeutics from Buy to Neutral and set a new price target of $12.00
Guggenheim downgraded Arcturus Therapeutics from Buy to Neutral
H.C. Wainwright resumed coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $60.00
Scotiabank initiated coverage of Arcturus Therapeutics with a rating of Sector Outperform and set a new price target of $32.00
BTIG Research initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $41.00
Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00
Canaccord Genuity initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $90.00
10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
DEF 14A - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
10-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
3 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
3 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
Fastest customizable press release news feed in the world
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in New York: 2026 Jefferies Global Healthcare Conference (Presentation) Thursday, June 4, 2026 (9:20 a.m. ET) Webcast link can be found under Investor Relations/Events section of Arcturus' website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare dis
Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine transcarbamylase (OTC) deficiency program; End of Phase 2 (EOP2) meeting H2 2026 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and prov
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings Conference Call Thursday, May 7, 2026, at 4:30 p.m. ET Domestic: 1-800-579-2543 International: 1-785-424-1789 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, Cal
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, s
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations/Events section of Arcturus' website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a messenger RNA medicines company focused on the development of liver a
ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. "Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical d
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3, 2026. Arcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Conference Call Tuesday, March 3, 2026, at 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS W
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRN
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference (Fireside Chat) Tuesday, December 2, 2025 (12:30 p.m. ET) About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa
Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants planned to start H1 2026 Additional cost reductions planned in fourth quarter to extend cash runway Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We were pleased to share the initi
Live Leadership Updates
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea
Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm
Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, including rare diseases. Dr. Sutherland is a pulmonologist by training with deep clinical knowledge combined with R&D and corporate strategy leadership across pulmonary and rare diseases. In connection with
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Jing Marantz, M.D., Ph.D., M.B.A., an experienced biopharma industry executive, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005321/en/Jing L Marantz, M.D., Ph.D., M.B.A. (Photo: Business Wire) "We are very pleased to welcome Dr. Jing Marantz, to the Arcturus Board," said Joseph Payne, President &
Live finance-specific insights
Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine transcarbamylase (OTC) deficiency program; End of Phase 2 (EOP2) meeting H2 2026 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and prov
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings Conference Call Thursday, May 7, 2026, at 4:30 p.m. ET Domestic: 1-800-579-2543 International: 1-785-424-1789 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, Cal
ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. "Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical d
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3, 2026. Arcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Conference Call Tuesday, March 3, 2026, at 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS W
Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants planned to start H1 2026 Additional cost reductions planned in fourth quarter to extend cash runway Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We were pleased to share the initi
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter ended September 30, 2025 after the market close on Monday, November 10 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 10, 2025. Arcturus Therapeutics Third Quarter 2025 Earnings Conference Call Monday, November 10, 2025, at 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link A
Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026 Seasonal flu (ARCT-2138) showed positive Phase 1 results BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, tod
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link Abou
Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun
This live feed shows all institutional transactions in real time.
SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)